Optimization of new sustainable synthetic processes: elimination of traditional toxic solvents

This PhD fellowship is a part of “IR2, green pharma” project. The project is an agreement between Huvepharma Italia Srl, University of Turin and Piedmont Region Institution. The project was developed in Huvepharma Italia Srl. The details concerning compounds, methods, customers, documents and patents are protected by trade secret. All information reported in this document are confidential and respect the Institutions agreement. During myPhD years, I worked in R&D lab in Huvepharma Italia SRL. Huvepharma is a pharmaceutical corporation, which produces API for human and animal diseases. During my period in Huvepharma, I was involved in the development of several API synthetic processes. In particular, our research team studied the scale up from laboratory size to plant of the pharmaceutical processes collaborating with plan production teams. During my first PhD year, I was in charge of the optimization of a new synthetic process commissioned by a costumer* concerning the production of an API (pharmaceutical active ingredient) of a nonsteroidal anti-inflammatory drug containing a sulfonamide moiety. The contract between Huvepharma and the costumer consisted of two phases: Phase 1: Preliminary process development supplied by costumers and the application of their analytical methods. Phase 2: Process validation by plant production and the checking of the expected quality of the product.